Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
West Pharmaceutical Services ( (WST) ) has provided an announcement.
On September 11, 2025, West Pharmaceutical Services announced the departure of Kimberly Banks MacKay, their Senior Vice President, General Counsel, and Corporate Secretary. The company has arranged for a transition period ending by December 31, 2025, to ensure a smooth handover of responsibilities, and expressed gratitude for Ms. MacKay’s contributions.
The most recent analyst rating on (WST) stock is a Buy with a $318.00 price target. To see the full list of analyst forecasts on West Pharmaceutical Services stock, see the WST Stock Forecast page.
Spark’s Take on WST Stock
According to Spark, TipRanks’ AI Analyst, WST is a Outperform.
West Pharmaceutical Services scores well due to strong financial performance and positive earnings call sentiment. Technical indicators show positive momentum, though valuation suggests the stock is relatively expensive. The company’s strategic initiatives and guidance revisions further enhance its outlook.
To see Spark’s full report on WST stock, click here.
More about West Pharmaceutical Services
West Pharmaceutical Services, Inc. operates in the pharmaceutical industry, focusing on the development and manufacturing of innovative solutions for injectable drug administration.
Average Trading Volume: 670,325
Technical Sentiment Signal: Hold
Current Market Cap: $18.35B
See more data about WST stock on TipRanks’ Stock Analysis page.